

# Srb7p is essential for the activation of a subset of genes

Anne Gromöller, Norbert Lehming\*

*Max-Delbrück-Laboratorium in der Max-Planck-Gesellschaft, Carl-von-Linné-Weg 10, 50829 Cologne, Germany*

Received 14 August 2000; revised 25 September 2000; accepted 29 September 2000

Edited by Giulio Superti-Furga

**Abstract** The mediator complex in the RNA polymerase II holoenzyme is known to be involved in transcriptional activation. The role of the essential mediator component Srb7p has been difficult to investigate, since no conditional lethal allele has been available to date. While the expression of Srb7p under the control of a repressible promoter is not sufficient to reduce the level of Srb7p beneath the threshold for survival, we have been able to isolate a clone termed *ts16* which confers a temperature sensitive phenotype. *ts16* contains an insertion mutation that requires translational frameshifting for correct expression of Srb7p, leading to extremely low protein levels. Strains bearing the *ts16* construct show mild defects in the transcription of constitutive genes like *TDH1* but severely affect activated transcription, e.g. of the *GAL1* gene. In contrast, *CUP1*, which is also independent of other holoenzyme components, is not affected by *ts16*. © 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.

**Key words:** Mediator; Holoenzyme; Transcription; Galactose induction; *Saccharomyces cerevisiae*

## 1. Introduction

Recruitment of the RNA polymerase II machinery is an important step in transcriptional activation [1,2]. Recent evidence suggests that the polymerase is brought to the promoter as a holoenzyme complex [3–5] containing a subset of the general transcription factors, the mediator subunit and the Swi/Snf complex [6]. The mediator subunit is sufficient to confer to an in vitro reconstituted transcription system the ability of responding to activator proteins [4]. It consists of 16 polypeptides including the Med proteins and a subset of the Srb (suppressor of RNA polymerase B) proteins [7]. The Med proteins have been identified biochemically because of their presence in the mediator [7,8] while the Srb proteins were discovered in a genetic screen with a truncated C-terminal domain (CTD) of the largest subunit of RNA polymerase II. Mutations in the Srb proteins were able to suppress the cold sensitive phenotype of yeast strains with such a CTD truncation [3,9]. Within the mediator, the Srb proteins 2, 4, 5 and 6 form a small subcomplex together with Med6p and Rox3p [10,11]. Of the Srb proteins, Srb proteins 4, 6 and 7 are essential. Studies with temperature sensitive (*ts*) alleles of *SRB4* and *SRB6* or deletion strains of *SRB2* and *SRB5*

have shown that these proteins are needed for efficient transcription of the vast majority of RNA polymerase II genes [3,12,13]. One of the notable exceptions is the *CUP1* gene, which is also independent of Kin28p, the kinase subunit of TFIIF [14,15]. In contrast to these Srb proteins, a *ts* mutant of Med6p was shown to selectively affect transcription of some activated yeast genes [16]. Even more specifically, mutations in Med9p or Med10p cause defects in the induction of only certain activated genes [17]. A conditional lethal mutant of Srb7p has not been available to date. Here we report that a *ts* allele of *SRB7* negatively affects transcription of some but not all genes to a moderate degree, while impairing the activation of a subset of genes.

## 2. Materials and methods

### 2.1. Yeast strains and plasmids

Parental yeast strains were JD53 (mating type *ura3–52 leu2–3–112 his3Δ200 lys2–801 trp1Δ63*), the isogenic strain JD52 [18] and strain NLY2 (mating type *gal4– gal80– ade– ura3–52 leu2–1 his3Δ200 trp1–1 lys2Δ3*) [19]. Strains JD53Δsrb7 and NLY2Δsrb7 were generated by first transforming plasmid YCplac33 [20] containing *SRB7* with its own promoter and terminator and then deleting the chromosomal copy of *SRB7* by homologous recombination with a linearised construct consisting of the *SRB7* promoter, the *LYS2* gene and the *SRB7* terminator. The resulting *Lys+* strains are suitable for the plasmid shuffle method. The plasmid Pgal1-SRB7 contains 660 bp *GAL1* promoter sequences and the coding sequence and terminator of *SRB7* generated by polymerase chain reaction (PCR), with the second codon exchanged from ACA to TAC (see text) in vector YCplac111 [20]. Strain JD53::Pgal1SRB6 was made by replacing the chromosomal *SRB6* promoter with the *TRP1* gene and 660 bp *GAL1* promoter sequences using a cassette consisting of *SRB6* upstream sequences, the *TRP1* gene, the *GAL1* promoter and the *SRB6* coding sequence with the second codon AGC replaced by TAC. The correct recombination was checked by growth phenotype and PCR with genomic DNA. Plasmid dihydrofolate reductase (*DHFR*)<sup>ts</sup>SRB7 contains the *CUP1* promoter and ubiquitin-*DHFR*<sup>ts</sup> sequences of pPW66R (*Bam*H1/*Bam*H1 and *Bam*H1/*Asp*718 fragments) [21] and the coding sequence and terminator of *SRB7* in vector YCplac22 [20]. In the original *ts16* construct, an *Escherichia coli* DNA sequence (see text) replaced the *Bam*H1-*Asp*718 fragment of pPW66R. In addition, there was a base insertion mutation in the third codon of *SRB7*. To eliminate the *CUP1* promoter, a PCR generated fragment containing all sequences downstream of the ATG of ubiquitin was subcloned into YCplac111. This construct was used in most experiments. A construct starting with the *E. coli* DNA sequence (compare Fig. 2) was also generated and tested for *ts* and mating defect phenotypes. Plasmid Pcup1GAL4 contains 450 bp *CUP1* promoter sequence and the coding sequence and terminator of *GAL4* in vector pRS314 [22]. Yeast cells were grown in YPDA or dropout medium [23]. Galactose media contained 2% galactose instead of glucose. 5-Fluoro orotic acid (FOA) medium contained 0.5 g/l FOA [24].

### 2.2. Primer extension

Yeast strain JD53Δsrb7 was transformed with plasmids *SRB7*wtYCplac111 or *ts16*, streaked on FOA medium to eliminate the *URA3* marked *SRB7*wt plasmid and cells were grown in YPDA medium. RNA was prepared as described [25] and primers (TTGCAGCTACCACATTGGCATTGGCACTCA for *CUP1* and

\*Corresponding author. Fax: (49)-221-5062613.  
E-mail: lehming@mpiz-koeln.mpg.de

**Abbreviations:** CTD, C-terminal domain; *DHFR*, dihydrofolate reductase; FOA, 5-fluoro orotic acid; ORF, open reading frame; Srb, suppressor of RNA polymerase B

AAACGAAATAAATCTCTTTGTAAAACGGTTCA for U6) were labelled with polynucleotide kinase [26]. Primer extension reactions were carried out following the protocol for aqueous hybridisation [27]. Samples were further treated according to [26] and resolved on a 6% polyacrylamide 7 M urea gel.

2.3. Northern blots

RNA preparation and Northern blot were carried out as described [25,26]. For the probes, gel purified PCR fragments of the ACT1, TDH1, GAL1 and MF $\alpha$ 1 coding sequences were labelled with Klenow fragment and random hexanucleotide primers. For CUP1, the promoter and coding sequence was used to generate a longer probe.

3. Results

3.1. Expression of *Srb7p* from a glucose repressed promoter still supports cell viability

In order to investigate the function of an essential protein like *Srb7p*, it is necessary to create a conditional lethal allele. One way to achieve this is to place the coding sequence of the gene in question under the control of a repressible promoter, e.g. the GAL1 promoter. The resulting yeast strain should be viable under inducing conditions (galactose) but non-viable under repressing conditions (glucose). To achieve faster deg-

radation of the protein after the switch from galactose to glucose medium, we changed the codon following the ATG to TAC, coding for tyrosine instead of threonine. According to the N-end rule, this should increase the turnover of the protein [28]. Surprisingly, the Pgal1-SRB7 construct supports cell viability also under repressing conditions, even at elevated temperature (Fig. 1A). However, a Western blot using  $\alpha$ Srb7p antibody confirmed that *Srb7p* expression in this strain was regulated in a carbon source dependent manner (Fig. 1B). In contrast to the results with *Srb7p*, placing SRB6 under the control of the GAL1 promoter in a similar strategy led to a conditional lethal strain as predicted (data not shown). For both the SRB6 and the SRB7 deletion, the entire open reading frame (ORF) had been deleted and the respective expression vectors contained the ORFs under the control of heterologous promoters and terminators. Therefore, we can exclude homologous recombination as a way for the promoterless SRB7 or the ts16 clone to support viability. In case that the unexpected result for *Srb7* was a peculiarity of the GAL1 promoter, we also tested the MET3 promoter which is repressed in the presence of methionine. But like Pgal1-SRB7, Pmet3-SRB7 also supports cell viability under inducing as well as repressing




Fig. 1. Expression of *Srb* proteins from a repressible promoter. A: Strain JD53 $\Delta$ srb7 was transformed with empty vector (left), SRB7wt on a LEU2-marked plasmid (middle) or a plasmid carrying the SRB7 coding sequence under the control of the GAL1 promoter (right). The construct is depicted on top; T→Y is a mutation of the second amino acid to achieve faster degradation, see text for details. The Pgal1-SRB7 strain can still grow under repressive conditions (glucose FOA medium). The control plates do not contain FOA and thus allow retention of the URA3 marked SRB7wt plasmid. The strain with empty vector does not contain any other source of SRB7 and cannot grow on FOA medium (left). B: Western blot showing the expression of *Srb7p* in strain JD53 $\Delta$ srb7 from the Pgal1-SRB7 plasmid in galactose medium (left) and its repression in glucose medium (middle). For comparison, the expression of *Srb7p* from its own promoter (SRB7wt) is shown (right). Two different exposures of the same blot are shown. The asterisk marks a non-specific band recognised by the  $\alpha$ Srb7p antibody.






Fig. 3. Transcription in strain JD53Δsrb7 bearing an SRB7wt plasmid or clone ts16. A: Primer extension analysis using a CUP1 specific primer. As a control for the reaction and loading efficiency a primer for the snRNA U6 was used in the same reaction (bottom). CUP1 transcription was induced by adding CuSO<sub>4</sub> to a final concentration of 50 μM 30 min prior to harvesting where indicated. Some cultures were incubated at the restrictive temperature for ts16 (36°C) for the indicated times. B: Northern blot with ACT1 and TDH1 probes. The rRNA and a blot with a CUP1 probe are given as controls.




Fig. 4. Effect of ts16 on GAL1 transcription. A: Northern blot with a GAL1 probe with strain JD53Δsrb7 bearing an SRB7wt plasmid (left) or clone ts16 (right). Cultures were induced by growth in 2% galactose medium for the indicated times. The incubation temperature was switched to 36°C 1 h prior to galactose induction. However, the marked decrease in GAL1 transcription caused by ts16 is also seen at 30°C (compare C). The rRNA and a CUP1 blot are given as controls. B: Growth phenotype on galactose medium. 10-fold serial dilutions of strain JD53Δsrb7 bearing an SRB7wt plasmid or clone ts16 were spotted onto glucose or galactose medium containing the indicated amounts of the respiration inhibitor antimycin A. C: Northern blot with a GAL1 probe with strain NLY2Δsrb7 bearing an SRB7wt plasmid or clone ts16 and a plasmid with the coding sequence of Gal4p under the control of the CUP1 promoter to ensure equal expression of Gal4p. Cells were grown at 30°C and induced in Trp<sup>-</sup> galactose medium (selecting for the GAL4 plasmid) for 4 h. The rRNA and a blot with a CUP1 probe are given as controls.

3.3. Clone *ts16* has no effect on transcription of *CUP1* and only minor effects on *ACT1* and *TDH1*

To investigate the role of *Srb7p* in transcription, the effects of clone *ts16* were analysed on the level of RNA. First, we looked at the *CUP1* message. *CUP1* was previously shown to be independent of both *Srb4p* [14] and *Kin28p* [15]. Fig. 3A shows a primer extension experiment with a strain bearing the clone *ts16* and a *CUP1* specific primer. As a control, a primer for the snRNA *U6* was used. *U6* is transcribed by RNA polymerase III and is therefore independent of the polymerase II specific *Srb7p*. *CUP1* is transcribed at equal levels in *SRB7wt* and *ts16* strains under induced and non-induced conditions, even after incubation at the restrictive temperature for the *ts16* clone. Thus *CUP1* transcription is independent not only of *Srb4p* and *Kin28p*, but also of *Srb7p*, and can be used as a control for further experiments. In Fig. 3B, the *ACT1* and *TDH1* messages were analysed by Northern blot. Both are expressed below wild-type level in the *ts16* strain even at the permissive temperature. Incubation at the restrictive temperature yields comparable results. In the example shown, both *ACT1* and *TDH1* expression were normalised to the *CUP1* expression that served as a control and quantitated to be two-fold reduced compared to the strain bearing the *SRB7wt* plasmid. In other experiments, the effect was even less pronounced. Clone *ts16* therefore has a detectable but minor effect on the expression of constitutive genes like *ACT1* and *TDH1*.




Fig. 5. Effect of *ts16* on mating factor expression. A: Northern blot with an *Mfα1* probe with strain *JD53Δsrb7* bearing an *SRB7wt* plasmid (left) or clone *ts16* (right). The *rRNA* and a blot with a *CUP1* probe are given as controls. B: Mating efficiency defect caused by *ts16*. Mixed cultures of *JD53Δsrb7* bearing an *SRB7wt* plasmid or clone *ts16* (both *Lys*<sup>+</sup>) and *JD52::His3* (*His*<sup>+</sup>) were grown overnight and 10-fold serial dilutions were spotted onto plates lacking histidine or lysine to control for equal concentrations of cells of both mating types and onto plates lacking both histidine and lysine selecting for diploid cells (bottom). Mating in the strain with clone *ts16* is less efficient.

3.4. Activation of *GAL1* and *MFα1* is impaired in strains bearing the *ts16* mutant

As an example for an inducible gene, we looked at the *GAL1* mRNA. As seen in Fig. 4A, *GAL1* expression is severely compromised in the strain bearing the *ts16* construct. This effect is observed at both 30 and 36°C. The defect in *GAL* gene expression also leads to a growth defect on galactose medium for the *ts16* strain. Transcription defects at the




Fig. 6. Model for the effects of clone *ts16*. In a strain with *ts16* as the only source for *Srb7p*, *Srb7p* is expressed at extremely low levels. Thus the majority of RNA polymerase II holoenzymes does not contain *Srb7p*. In the case of constitutive expression, the lack of *Srb7p* leads to only minor effects. *Srb7p* is not essential for this process, but structural changes in the holoenzymes lacking *Srb7p* may lead to minor defects (top). In contrast, *Srb7p* is required for activated transcription, e.g. at the *GAL1* promoter. If only a small fraction of holoenzymes contains *Srb7p*, transcription from these promoters is severely compromised (bottom).

permissive temperature are commonly found for the *ts* alleles of transcription factors [29–31], especially if they display a slow growth phenotype as does the *ts16* strain. However, while the slow growth phenotype of a *ts16* strain is more pronounced on galactose than on glucose medium, the growth defect only becomes really apparent in the presence of the respiration inhibitor antimycin A (Fig. 4B). The effect of *ts16* on *GAL1* expression could be a direct or indirect effect. Since *GAL1* transcription is activated by Gal4p, *ts16* might simply reduce Gal4p levels and thus prevent *GAL1* activation. To rule out this possibility, we used a *GAL4* deletion strain with a construct containing the *GAL4* coding sequence under the control of the *CUP1* promoter. In this strain, Gal4p should be expressed at equal levels in the wt and *ts16* strain, because the *CUP1* promoter is not influenced by *ts16* (Fig. 3A). The experiment depicted in Fig. 4C demonstrates that under these conditions, *GAL1* expression is still impaired in strain *ts16*, arguing that the effect is direct. To test if clone *ts16* has a similar effect on other activated genes, we looked at the mRNA levels of the mating factor *MF $\alpha$ 1*. Similarly as for *GAL1*, *MF $\alpha$ 1* expression was reduced to background levels in a *ts16* strain (Fig. 5A). Again, this transcriptional defect corresponds to a phenotype, since mating efficiency in strain *ts16* is reduced (Fig. 5B).

#### 4. Discussion

In experiments with *SRB7* constructs under the control of repressible promoters or with the heat inducible degron system we have been able to demonstrate that low levels of *Srb7p* are still sufficient for cell survival. When using repressible promoters, another explanation might also account for the lack of an effect: if *Srb7p* were itself necessary for repression, a kind of feedback loop would prevent the protein level from dropping beneath the threshold necessary to keep up the repression at the promoter used in the *SRB7* construct. The question of repression, however, was not addressed in this study. We used the conditional lethal *SRB7* allele *ts16* to study the role of *Srb7p* in constitutive and activated transcription. The *ts16* construct lacks a bona fide yeast promoter and contains *E. coli* DNA sequences instead. In addition, it contains a frameshift mutation that creates a stop codon just after the ATG. Since the N-terminus turned out to be essential for *Srb7p* function it must, at least in part, be expressed correctly from clone *ts16*. The event of such a translational frameshifting leading to a 100-fold reduction in protein levels is a known phenomenon in yeast [32]. We propose that frameshifting occurs at a low frequency and that the extremely low level of *Srb7p* in *ts16* cells is responsible for the *ts* phenotype. However, the *E. coli* DNA sequences are also needed in the *ts16* clone to allow cell survival. They may exert an effect at the level of transcription or RNA stability, but most likely they influence the frameshifting event. Since the *araB* coding sequence in the *E. coli* DNA is in frame with the ATG of *SRB7*, a possible explanation is that *ts16* cells express a fusion protein, with the N-terminal extension facilitating the translational frameshifting that would otherwise have to occur extremely close to the translational start site. In this case, the N-terminal extension might also contribute to the effects elicited by clone *ts16*. A direct demonstration of the putative fusion protein has not been possible, due to too many cross-reacting bands produced by the anti-*Srb7p* anti-

body in the relevant area of the Western blot (data not shown).

The analysis of transcription in strains bearing the *ts16* clone defined three kinds of genes. First, transcription of the *CUP1* gene was not affected by *ts16*. Since *CUP1* is also independent of *Srb4p* and *Kin28p* [14,15], this result confirms its exceptional status. All other genes tested were affected by *ts16*, but to very different degrees. While the expressions of the constitutive genes *ACT1* and *TDH1* was only mildly reduced, expression of the activated genes *GAL1* and *MF $\alpha$ 1* was almost completely impaired. We propose that the minor effects on e.g. *TDH1* transcription are not due to a direct role of *Srb7p* in this process but rather to an indirect effect such as a structural change in holoenzymes lacking the *Srb7* protein (Fig. 6). The dramatic effect on *GAL1* and *MF $\alpha$ 1* transcription, however, argues that *Srb7p* is essential for activated transcription from these promoters. This behaviour of the *ts16* strain resembles that of a *Med6p* *ts* mutant, which also selectively affects activated transcription [16]. In a more recent study, it was proposed that signals of activator proteins to different mediator subunits might be transmitted to *Med6p* as a central regulatory subunit [17]. Since *Med6p* is part of the small mediator subcomplex while *Srb7p*, like potential activator targets such as *Med9p* or *Med10p*, is localised in the large subcomplex [11], one might speculate that *Srb7p* acts between the two. It will be very interesting to more closely define the relationship between *Med6p* and *Srb7p*.

*Acknowledgements:* This work was supported by grants from the Bundesministerium für Bildung und Forschung (BMBF) and the Max-Planck-Society (MPG) to N.L.

#### References

- [1] Ptashne, M. and Gann, A. (1997) *Nature* 386, 569–577.
- [2] Keaveney, M. and Struhl, K. (1998) *Mol. Cell* 1, 917–924.
- [3] Thompson, C.M., Koleske, A.J., Chao, D.M. and Young, R.A. (1993) *Cell* 73, 1361–1375.
- [4] Kim, Y.J., Björklund, S., Li, Y., Sayre, M.H. and Kornberg, R.D. (1994) *Cell* 77, 599–608.
- [5] Kuras, L. and Struhl, K. (1999) *Nature* 399, 609–613.
- [6] Myer, V.E. and Young, R.A. (1998) *J. Biol. Chem.*
- [7] Myers, L.C., Gustafsson, C.M., Bushnell, D.A., Lui, M., Erdjument-Bromage, H., Tempst, P. and Kornberg, R.D. (1998) *Genes Dev.* 12, 45–54.
- [8] Gustafsson, C.M., Myers, L.C., Beve, J., Spahr, H., Lui, M., Erdjument-Bromage, H., Tempst, P. and Kornberg, R.D. (1998) *J. Biol. Chem.* 273, 30851–30854.
- [9] Nonet, M.L. and Young, R.A. (1989) *Genetics* 123, 715–724.
- [10] Koh, S.S., Ansari, A.Z., Ptashne, M. and Young, R.A. (1998) *Mol. Cell* 1, 895–904.
- [11] Lee, Y.C. and Kim, Y.-J. (1998) *Mol. Cell. Biol.* 18, 5364–5370.
- [12] Thompson, C.M. and Young, R.A. (1995) *Proc. Natl. Acad. Sci. USA* 92, 4587–4590.
- [13] Lee, Y.C., Park, J.M., Min, S., Han, S.J. and Kim, Y.-J. (1999) *Mol. Cell. Biol.* 19, 2967–2976.
- [14] McNeil, J.B., Agah, H. and Bentley, D. (1998) *Genes Dev.* 12, 2510–2521.
- [15] Lee, D. and Lis, J.T. (1998) *Nature* 393, 389–392.
- [16] Lee, Y.C., Min, S., Gim, B.S. and Kim, Y.-J. (1997) *Mol. Cell. Biol.* 17, 4622–4632.
- [17] Han, S.J., Lee, Y.C., Gim, B.S., Ryu, G.-H., Park, S.J., Lane, W.S. and Kim, Y.-J. (1999) *Mol. Cell. Biol.* 19, 979–988.
- [18] Dohmen, R.J., Stappen, R., McGrath, J.P., Forrova, H., Kolarov, J., Goffeau, A. and Varshavsky, A. (1995) *J. Biol. Chem.* 270, 18099–18109.
- [19] Saha, S., Brickman, J.M., Lehming, N. and Ptashne, M. (1993) *Nature* 363, 648–652.

- [20] Gietz, R.D. and Sugino, A. (1988) *Gene* 74, 527–534.
- [21] Dohmen, R.J., Wu, P. and Varshavsky, A. (1994) *Science* 263, 1273–1276.
- [22] Sikorski, R.S. and Hieter, P. (1989) *Genetics* 122, 19–27.
- [23] Sherman, F. (1991) *Methods Enzymol.* 194, 3–21.
- [24] Boeke, J.D., Trueheart, J., Natsoulis, G. and Fink, G.R. (1987) *Methods Enzymol.* 154, 164–175.
- [25] Ma, J. and Ptashne, M. (1987) *Cell* 48, 847–853.
- [26] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- [27] Boorstein, W.R. and Craig, E.A. (1989) *Methods Enzymol.* 180, 347–369.
- [28] Varshavsky, A. (1996) *Proc. Natl. Acad. Sci. USA* 93, 12142–12149.
- [29] Stargell, L.A. and Struhl, K. (1996) *Mol. Cell. Biol.* 16, 4456–4464.
- [30] Li, X.-Y., Virbasius, A., Zhu, X. and Green, M.R. (1999) *Nature* 399, 605–609.
- [31] Galarneau, L. et al. (2000) *Mol. Cell* 5, 927–937.
- [32] Farabaugh, P.J. (1996) *Microbiol. Rev.* 60, 103–134.